Table 2 Sample characteristics
Centre A | Centre B | Centre C | Centre D | Centre E | All five CGSs | |
|---|---|---|---|---|---|---|
Sample response | ||||||
Pre-counsel | 52 (100%) | 52 (100%) | 49 (100%) | 52 (100%) | 51 (100%) | 256 (100%) |
1 month | 45 (86%) | 45 (86%) | 48 (98%) | 48 (92%) | 48 (94%) | 234 (91%) |
12 months | 40 (77%) | 37 (71%) | 39 (80%) | 43 (83%) | 43 (84%) | 202 (79%) |
All three | 36 (69%) | 36 (69%) | 39 (80%) | 41 (79%) | 40 (78%) | 192 (75%) |
Sociodemographics | ||||||
Gender (% male) | 6% | 17% | 0% | 7% | 0% | 6% |
Mean age (years), range | 40 (24, 63) | 41 (24, 72) | 42 (23, 68) | 43 (22, 67) | 40 (23, 61) | 41 (22, 72) |
Ethnic minority | 0 | 1 (3%) | 3 (8%) | 0 | 0 | 4 (2%) |
University educated | 61% | 42% | 62% | 34% | 35% | 46% |
Professional or managerial | 50% | 26% | 53% | 48% | 31% | 42% |
Site of familial cancer | ||||||
Breast | 69% | 61% | 74% | 71% | 98% | 75% |
Bowel | 6% | 33% | 23% | 24% | 0 | 17% |
Ovary | 25% | 6% | 8% | 7% | 3% | 9% |
Other | 0 | 3% | 3% | 5% | 0 | 2% |
Risk level (clinician estimate) | ||||||
Population-level risk | 17% | 14% | 18% | 20% | 26% | 19% |
Moderate risk | 35% | 56% | 50% | 63% | 69% | 56% |
High risk | 48% | 31% | 32% | 26% | 5% | 25% |
